Equity Overview
Price & Market Data
Price: $17.53
Daily Change: +$0.39 / 2.22%
Daily Range: $17.52 - $17.53
Market Cap: $1,071,753,984
Daily Volume: 597
Performance Metrics
1 Week: 16.36%
1 Month: 20.11%
3 Months: -24.26%
6 Months: -68.79%
1 Year: 95.66%
YTD: -28.37%
Company Details
Employees: 221
Sector: Health technology
Industry: Biotechnology
Country: Netherlands
Details
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.